Arcutis Biotherapeutics
ARQT | NASDAQ
$27.15
-$1.11 (-3.93%)
At close: Nov 16, 2026, 4:00 PM ET
$25.79
-$1.36 (-5.01%)
After-hours:
Nov 16, 2026, 7:32 PM ET
Arcutis Biotherapeutics Company Profile
Company profile explainedCompany Profile
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Key Executives
| Name | Position |
|---|---|
| Todd Franklin Watanabe | President, Chief Executive Officer & Director |
| Latha Vairavan | Senior Vice President & Chief Financial Officer |
| Masaru Matsuda | Executive VP, Chief Legal Officer & Corporate Secretary |
| Aleen Hosdaghian | Vice President of Marketing |
| Amanda Sheldon | Head of Corporate Communications |
| Bhaskar Chaudhuri | Co-Founder & Director Emeritus |
| Brian Schoelkopf | Head of Investor Relations |
| Patrick E. Burnett | Executive Vice President & Chief Medical Officer |
| Steve Arias | Vice President of Compliance & Privacy |
| Todd Tucker | Senior Vice President & Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 3 | Filing |
| Oct 28, 2026 | 4 | Filing |
| Oct 28, 2026 | 8-K | Current Report |
| Oct 19, 2026 | 4 | Filing |
| Oct 05, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 18, 2026 | 4 | Filing |
| Sep 17, 2026 | 4 | Filing |
| Sep 10, 2026 | 4 | Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 24, 2026 | 4 | Filing |
Arcutis Biotherapeutics
| Country | United States |
| IPO Date | Jan 31, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 354 |
| CEO | Todd Franklin Watanabe |
Contact Details
3027 Townsgate Road Westlake Village,
California 91361 United States
Stock Details
| Ticker Symbol | ARQT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001787306 |
| CUSIP Number | 03969K108 |
| ISIN Number | US03969K1088 |
| SIC Code | 2834 |
Recent News
- 3 days ago / globenewswire.comArcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific Meeting
- 12 days ago / globenewswire.comArcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
- 12 days ago / seekingalpha.comArcutis Biotherapeutics, Inc. (ARQT) Q3 2026 Earnings Call Transcript
- 12 days ago / marketbeat.comArcutis Biotherapeutics Q3 Earnings Call Highlights
- 12 days ago / zacks.comArcutis Biotherapeutics, Inc. (ARQT) Misses Q3 Earnings Estimates
- 20 days ago / zacks.comArcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth
- 20 days ago / globenewswire.comArcutis Appoints Rob Scott, MD to Board of Directors
- 20 days ago / globenewswire.comArcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
- 26 days ago / globenewswire.comArcutis to Report Third Quarter 2026 Financial Results and Host Conference Call on November 4, 2026
- 1 month ago / benzinga.comWhy Is Arcutis Biotherapeutics Stock Surging Thursday?
Add to Watchlist
Select watchlists to add or remove ARQT